Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs W W Grainger Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while W W Grainger Inc trades at $1,365.59 (market cap $64.73B). The key difference: W W Grainger Inc is far larger — about 8.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and W W Grainger Inc pays a 0.68% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GWW | |
|---|---|---|
Market Cap | $8.04B | $64.73B |
Sector | Health | Technology |
52-Week High | $339.75 | $1.39K |
52-Week Low | $241.71 | $918.18 |
Enterprise Value | $7.85B | $66.82B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
GWW trades at $1,391.68, up 1.16% today, with a bullish technical outlook supported by moving averages and strong momentum. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised its full-year guidance. Revenue growth remains steady, with 2026 revenue projected at $18.4B, while profitability metrics like ROE of 48.1% and net margin near 10% highlight operational strength. Positive analyst sentiment and recent dividend declarations reinforce investor confidence amid a favorable market backdrop.
The outlook for GWW is positive, driven by earnings beats and raised guidance, though valuation multiples like a P/E of 36.87 suggest premium pricing. Risks include economic sensitivity and competitive pressures, but institutional buy ratings and technical support near $1,380 provide a cushion for upward momentum if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
